According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 9372770-00010
 Date of first issue: 27.08.2021

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Bezlotoxumab Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Pharmaceutical

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

120 Moorgate

EC2M 6UR London, United Kingdom

Telephone : +44 (0) 2081548000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Not a hazardous substance or mixture.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 9372770-00010
 Date of first issue: 27.08.2021

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Bezlotoxumab	1246264-45-8		>= 1 - < 10

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

Protection of first-aiders : No special precautions are necessary for first aid responders.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.

Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

None known.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Bezlotoxumab Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 9372770-00010 Date of first issue: 27.08.2021 4.1

Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

ucts

5.3 Advice for firefighters

Special protective equipment:

for firefighters

Wear self-contained breathing apparatus for firefighting if nec-

essary. Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Follow safe handling advice (see section 7) and personal pro-Personal precautions

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

If spillage enters rivers or watercourses, inform the Environment Agency (emergency telephone number 0800 807060).

6.3 Methods and material for containment and cleaning up

Soak up with inert absorbent material. Methods for cleaning up

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 9372770-00010
 Date of first issue: 27.08.2021

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation :

Advice on safe handling : Handle in accordance with good industrial hygiene and safety

Use only with adequate ventilation.

practice, based on the results of the workplace exposure as-

sessment

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage

areas and containers

Keep in properly labelled containers. Store in accordance with

the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Bezlotoxumab	1246264- 45-8	TWA	5.0 mg/m3 (OEB 1)	Internal

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Bezlotoxumab Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 9372770-00010 Date of first issue: 27.08.2021 4.1

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

Personal protective equipment

Eye/face protection Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material Chemical-resistant gloves

Skin and body protection Work uniform or laboratory coat.

Respiratory protection If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to BS EN 143

Filter type Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance Aqueous solution

Colour Colorless to pale yellow

Odour No data available Odour Threshold No data available

5.7 - 6.3pН

Melting point/freezing point No data available

Initial boiling point and boiling

range

No data available

No data available Flash point

No data available Evaporation rate

Flammability (solid, gas) Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure No data available

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 9372770-00010
 Date of first issue: 27.08.2021

Relative vapour density : No data available

Relative density : No data available

Density : 1.0146 g/cm³

Solubility(ies)

Water solubility : No data available Partition coefficient: n- : Not applicable

octanol/water

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : 1.2 mPa.s (25 °C)

Viscosity, kinematic : 1.833 mm2/s (4 °C)

1.183 mm2/s (25 °C)

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : No data available

Molecular weight : No data available

Particle size : Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Bezlotoxumab Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 9372770-00010 Date of first issue: 27.08.2021 4.1

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of: Inhalation Skin contact exposure

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Bezlotoxumab:

Acute toxicity (other routes of : LD50 (Mouse): > 125 mg/kg

administration)

Application Route: Intravenous

Remarks: No adverse effect has been observed in acute tox-

icity tests.

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 9372770-00010
 Date of first issue: 27.08.2021

Repeated dose toxicity

Components:

Bezlotoxumab:

Species : Mouse
NOAEL : 50 mg/kg
Application Route : Intravenous

Exposure time : 15 d

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 125 mg/kg
Application Route : Intravenous

Exposure time : 21 d

Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Bezlotoxumab:

Inhalation : Symptoms: Nausea, Headache, Diarrhoea, Fever

SECTION 12: Ecological information

12.1 Toxicity

No data available

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting poten: This substance/mixture does not contain components consid-

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 9372770-00010
 Date of first issue: 27.08.2021

tial ered to have endocrine disrupting properties for environment

according to UK REACH Article 57(f).

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 9372770-00010
 Date of first issue: 27.08.2021

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA (Cargo) : Not regulated as a dangerous good

IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17) : Not applicable

UK REACH Candidate list of substances of very high : Not applicable

concern (SVHC) for Authorisation

The Persistent Organic Pollutants Regulations (retained : Not applicable

Regulation (EU) 2019/1021 as amended for Great Brit-

ain)

Regulation (EC) on substances that deplete the ozone : Not applicable

laver

UK REACH List of substances subject to authorisation : Not applicable

(Annex XIV)

GB Export and import of hazardous chemicals - Prior : Not applicable

Informed Consent (PIC) Regulation

Control of Major Accident Hazards Regulations 2015 (COMAH)

Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Bezlotoxumab Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 9372770-00010 Date of first issue: 27.08.2021 4.1

> are highlighted in the body of this document by two vertical lines.

Full text of other abbreviations

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance: PICCS - Philippines Inventory of Chemicals and Chemical Substances: (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to : compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Bezlotoxumab Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.1
 28.09.2024
 9372770-00010
 Date of first issue: 27.08.2021

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN